These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12115876)

  • 1. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis.
    Nakopoulou L; Giannopoulou I; Stefanaki K; Panayotopoulou E; Tsirmpa I; Alexandrou P; Mavrommatis J; Katsarou S; Davaris P
    J Pathol; 2002 Jul; 197(3):307-13. PubMed ID: 12115876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases.
    Ree AH; Florenes VA; Berg JP; Maelandsmo GM; Nesland JM; Fodstad O
    Clin Cancer Res; 1997 Sep; 3(9):1623-8. PubMed ID: 9815852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer.
    Nakopoulou L; Katsarou S; Giannopoulou I; Alexandrou P; Tsirmpa I; Panayotopoulou E; Mavrommatis J; Keramopoulos A
    Mod Pathol; 2002 Jan; 15(1):26-34. PubMed ID: 11796838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P; Akram M; Benezra R; Brogi E
    Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
    Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
    Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.
    Kuvaja P; Hulkkonen S; Pasanen I; Soini Y; Lehtonen S; Talvensaari-Mattila A; Pääkkö P; Kaakinen M; Autio-Harmainen H; Hurskainen T; Lehenkari P; Turpeenniemi-Hujanen T
    Exp Cell Res; 2012 Jun; 318(10):1094-103. PubMed ID: 22465225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas.
    Gakiopoulou H; Nakopoulou L; Siatelis A; Mavrommatis I; Panayotopoulou EG; Tsirmpa I; Stravodimos C; Giannopoulos A
    Clin Cancer Res; 2003 Nov; 9(15):5573-81. PubMed ID: 14654538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromelysin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patients' outcome.
    Nakopoulou L; Panayotopoulou EG; Giannopoulou I; Alexandrou P; Katsarou S; Athanassiadou P; Keramopoulos A
    Mod Pathol; 2002 Nov; 15(11):1154-61. PubMed ID: 12429794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
    Buttitta F; Felicioni L; Barassi F; Martella C; Paolizzi D; Fresu G; Salvatore S; Cuccurullo F; Mezzetti A; Campani D; Marchetti A
    J Pathol; 2006 Feb; 208(3):350-5. PubMed ID: 16353168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
    Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
    Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer.
    Nakamura Y; Yasuoka H; Tsujimoto M; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Breast Cancer Res Treat; 2005 May; 91(2):125-32. PubMed ID: 15868440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between tissue inhibitors of metalloproteinase and metastasis and prognosis in breast cancer].
    Jiang X; Huang X; Li J; Shi Y; Zhou L
    Zhonghua Wai Ke Za Zhi; 2000 Apr; 38(4):291-3, 19. PubMed ID: 12828172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.